From the Departments of Plastic Reconstructive and Aesthetic Surgery, Pathology, and Pharmacology, Hacettepe University Faculty of Medicine.
Plast Reconstr Surg. 2022 Nov 1;150(5):1005e-1014e. doi: 10.1097/PRS.0000000000009653. Epub 2022 Aug 22.
Capsular contracture is the most common complication following breast augmentation. Recently, prophylaxis studies aiming to inhibit the release of profibrotic substances to prevent capsular contracture have gained in importance. This study investigated the effects of cromolyn sodium, montelukast, and zafirlukast on capsular contracture in a rat model.
Thirty female Wistar albino rats were randomly divided into five groups: control, sham, cromolyn sodium, montelukast, and zafirlukast. Intraperitoneal injections were administered daily to the sham (1 ml per day), cromolyn sodium (10 mg/kg per day), montelukast (10 mg/kg per day), and zafirlukast (1.25 mg/kg per day) groups 1 month before surgery. Miniature breast implants were then placed on the backs of the rats in each group. Injections were continued for the next 3 months. The rats were subsequently killed, and the capsules were harvested and assessed histopathologically. The histopathologic outcomes were acute inflammation status, inflammation severity, synovial metaplasia, foreign body reaction, mast cell count, and capsular thickness.
The cromolyn sodium, montelukast, and zafirlukast groups had less acute inflammation and lower mean inflammation severity scores, foreign body reaction occurrence, mast cell counts, and capsular thickness than the control and sham groups ( p < 0.05). These parameters were better in the cromolyn sodium group than in the montelukast and zafirlukast groups ( p < 0.05).
Cromolyn sodium appears to inhibit capsular contracture more efficiently than montelukast and zafirlukast. This report may be a pioneer study for the prophylactic use of cromolyn sodium in capsular contracture.
The prophylactic administration of cromolyn sodium appears to reduce capsular contracture more efficiently than that of montelukast and zafirlukast. This report might constitute a pioneer study for the prophylactic use of cromolyn sodium in capsular contracture.
包膜挛缩是乳房增大术后最常见的并发症。最近,旨在抑制释放纤维生成物质以预防包膜挛缩的预防研究变得越来越重要。本研究在大鼠模型中研究了色甘酸钠、孟鲁司特和扎鲁司特对包膜挛缩的影响。
将 30 只雌性 Wistar 白化大鼠随机分为五组:对照组、假手术组、色甘酸钠组、孟鲁司特组和扎鲁司特组。在手术前 1 个月,假手术组(每天 1ml)、色甘酸钠组(每天 10mg/kg)、孟鲁司特组(每天 10mg/kg)和扎鲁司特组(每天 1.25mg/kg)每天进行腹腔注射。然后在每组大鼠的背部放置微型乳房植入物。注射持续进行 3 个月。随后处死大鼠,取出胶囊并进行组织病理学评估。组织病理学结果包括急性炎症状态、炎症严重程度、滑膜化生、异物反应、肥大细胞计数和包膜厚度。
与对照组和假手术组相比,色甘酸钠组、孟鲁司特组和扎鲁司特组的急性炎症较轻,平均炎症严重程度评分、异物反应发生率、肥大细胞计数和包膜厚度较低(p<0.05)。色甘酸钠组的这些参数优于孟鲁司特组和扎鲁司特组(p<0.05)。
色甘酸钠似乎比孟鲁司特和扎鲁司特更有效地抑制包膜挛缩。本报告可能是色甘酸钠预防包膜挛缩的首例研究。
预防性给予色甘酸钠似乎比孟鲁司特和扎鲁司特更能有效地减少包膜挛缩。本报告可能构成色甘酸钠预防包膜挛缩的首例研究。